Drug Profile
TI 061
Alternative Names: TI-061Latest Information Update: 05 Oct 2020
Price :
$50
*
At a glance
- Originator Tioma Therapeutics
- Developer Arch Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 05 Oct 2020 No development reported - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in United Kingdom (IV) (Arch Oncology Website, October 2020)
- 05 Oct 2020 No development reported - Phase-I/II for Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (IV) (Arch Oncology Website, October 2020)
- 23 Jan 2018 Tioma Therapeutics is now called Arch Oncology